XM does not provide services to residents of the United States of America.
C
C

Cronos

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Cannabis firms gain as Trump shows support for reclassification

BUZZ-Cannabis firms gain as Trump shows support for reclassification ** Shares of cannabis firms rise after Republican presidential candidate Donald Trump expresses support for reclassification of marijuana at the federal level ** Trump says he will vote "yes" over an amendment in Florida that will legalize recreational marijuana and recommended Congress to pass the SAFE banking act and other reforms, according to his post on Truth Social ** Cannabis advocacy group National Cannabis Roundtable t
C
C

U.S. STOCKS Lumen Technologies, Insulet, PDD Holdings

BUZZ-U.S. STOCKS ON THE MOVE-Lumen Technologies, Insulet, PDD Holdings Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 rose on Tuesday in mixed trading ahead of a highly anticipated quarterly report from Nvidia and economic data expected later in the week.
N
W
U
U
C
M
R

U.S. STOCKS Eli Lilly, JD.com, Super Micro Computer

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, JD.com, Super Micro Computer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were lower on Tuesday, weighed down by tech-related stocks, as caution prevailed ahead of a highly anticipated earnings report from Nvidia and crucial economic data expected later in the week.
N
U
U
C
M
R

Pot stocks fall as US drug agency to hold reclassification hearing after elections

BUZZ-Pot stocks fall as US drug agency to hold reclassification hearing after elections ** U.S.-listed shares of cannabis firms fall in premarket trade ** Shares slide as Drug Enforcement Administration said hearing on the proposal to reclassify marijuana to a Schedule III drug will take place on Dec. 2, after the U.S. presidential elections ** SND
A
C
C

Cronos Group Inc reports results for the quarter ended in January - Earnings Summary

Cronos Group Inc reports results for the quarter ended in January - Earnings Summary Cronos Group Inc CRON.TO reported a quarterly adjusted loss of 2 cents​​ per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of -1 cents. The mean expectation of four analysts for the quarter was for breakeven results per share.
C

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.